Cohort profile: The inflammatory bowel disease South Limburg cohort (IBDSL)

International Journal of Epidemiology

Volumn 46, Issue 2, 2017, Pages

  Van Den Heuvel, Tim RA ^a   Jonkers, Daisy M ^a   Jeuring, Steven FG ^a   Romberg Camps, Marielle JL ^b   Oostenbrug, Liekele E ^b   Zeegers, Maurice P ^a   Masclee, Ad A ^a   Pierik, Marie J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

Biobank; Cohort; Crohn s disease; Epidemiology; Inflammatory bowel disease; Molecular epidemiology; Population based; Ulcerative colitis

Indexed keywords

BACTERIAL DISEASE; BIOMARKER; COHORT ANALYSIS; DATABASE; EPIDEMIOLOGY; IMMUNE RESPONSE; MICROORGANISM; PUBLIC HEALTH; QUALITY OF LIFE; RISK FACTOR;

ARTICLE; BIOBANK; COHORT ANALYSIS; CROHN DISEASE; FOLLOW UP; FUTUROLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; MOLECULAR EPIDEMIOLOGY; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION; ULCERATIVE COLITIS; ADULT; CROSS-SECTIONAL STUDY; FEMALE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SPECIMEN HANDLING; YOUNG ADULT;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; SPECIMEN HANDLING; YOUNG ADULT;

EID: 85040719590     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyv088     Document Type: Article

References (76)

1. Romberg-Camps MJ, Bol Y, Dagnelie PC et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010;16:2137–47.
2. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005;11:909–18.
3. Casellas F, Arenas JI, Baudet JS et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11:488–96.
4. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014;20:91–99.
5. Stockbrugger RW, Russel MG, van Blankenstein M, Shivananda S. EC-IBD: a European effort in inflammatory bowel disease. Eur J Intern Med 2000;11:187–90.
6. StatisticsNetherlands. 2014. http://statline.cbs.nl/Statweb/.
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16–19.
8. Casparie M, Tiebosch AT, Burger G et al. Pathology databank-ing and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29:19–24.
9. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
10. Jeuring S, Van den Heuvel T, Zeegers M et al. OP005. Is elderly-onset ulcerative colitis a different entity? – Natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis 2014;8: S3–S4.
11. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.
12. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29–32.
13. Biobank (MUMCþ). 2014. http://www.biobank.nl/.
14. Daperno M, D’Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60: 505–12.
15. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317: 1625–29.
16. Sysmed-IBD. 2012. http://www.sysmedibd.eu/.
17. IBD-BIOM. 2012. http://www.ibdbiom.eu/.
18. IBD-Character. 2012. http://www.ibdcharacter.eu/.
19. Romberg-Camps M, Kuiper E, Schouten L et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis 2010;16:1397–410.
20. Romberg-Camps MJ, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009;104:371–83.
21. Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ et al. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis 2009;3: 115–24.
22. Russel MG, Dorant E, Brummer RJ et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997;113:377–82.
23. Russel MG, Dorant E, Volovics A et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998;41:33–40.
24. Russel MG, Engels LG, Muris JW et al. Modern life in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998;10:243–49.
25. Russel MG, Nieman FH, Bergers JM, Stockbrugger RW. Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol 1996;8:1075–81.
26. Russel MG, Pastoor CJ, Brandon S et al. Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): a health-related quality of life questionnaire in inflammatory bowel disease. Digestion 1997;58:282–88.
27. Russel MG, Pastoor CJ, Janssen KM et al. Familial aggregation of inflammatory bowel disease: a population-based study in South Limburg, The Netherlands. The South Limburg IBD Study Group. Scand J Gastroenterol Suppl 1997;223:88–91.
28. Russel MG, Ryan BM, Dagnelie PC et al. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut 2003;52:358–62.
29. Russel MG, Stockbrugger RW. Is appendectomy a causative factor in ulcerative colitis? Eur J Gastroenterol Hepatol 1998;10: 455–57.
30. Russel MG, Volovics A, Schoon EJ et al. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis 1998;4:182–86.
31. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut 2006;55:1124–30.
32. Wolters FL, Russel MG, Sijbrandij J et al. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510–18.
33. Wolters FL, Russel MG, Sijbrandij J et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 2006;243:46–54.
34. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn’s disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483–96.
35. Wolters FL, van Zeijl G, Sijbrandij J et al. Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol 2005;11:7152–58.
36. Boonen A, Dagnelie PC, Feleus A et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis 2002;8:382–89.
37. Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 2003;125:982–84.
38. van der Eijk I, Sixma H, Smeets T et al. Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results. Am J Gastroenterol 2001; 96:3329–36.
39. van der Eijk I, Stockbrugger R, Russel M. Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. Eur J Intern Med 2000;11:228–34.
40. Van Der Eijk I, Verheggen FW, Russel MG et al. “Best practice” in inflammatory bowel disease: an international survey and audit. Eur J Intern Med 2004;15:113–20.
41. van der Eijk I, Vlachonikolis IG, Munkholm P et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis 2004;10:392–98.
42. Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001;15: 399–403.
43. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998;67: 919–26.
44. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000;54:514–21.
45. Geerling BJ, Badart-Smook A, van Deursen C et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn’s disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000;6: 77–84.
46. Geerling BJ, Dagnelie PC, Badart-Smook A, Russel MG, Stockbrugger RW, Brummer RJ. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol 2000;95: 1008–13.
47. Geerling BJ, Stockbrugger RW, Brummer RJ. Nutrition and inflammatory bowel disease: an update. Scand J Gastroenterol Suppl 1999;230:95–105.
48. Gilissen LP, Bierau J, Derijks LJ et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005;22:605–11.
49. Gilissen LP, Derijks LJ, Driessen A et al. Toxicity of 6-thiogua-nine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis 2007;39:156–59.
50. Hoie O, Aamodt G, Vermeire S et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis 2008;2:114–22.
51. Hoie O, Schouten LJ, Wolters FL et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007;56:497–503.
52. Hoie O, Wolters F, Riis L et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102: 1692–701.
53. Isene R, Bernklev T, Hoie O et al. Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort. Scand J Gastroenterol 2014; 49:820–25.
54. Juillerat P, Pittet V, Mottet C et al. Appropriateness of early management of newly diagnosed Crohn’s disease in a European population-based cohort. Scand J Gastroenterol 2010;45: 1449–56.
55. Katsanos KH, Tatsioni A, Pedersen N et al. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. J Crohns Colitis 2011; 5:430–42.
56. Katsanos KH, Vermeire S, Christodoulou DK et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative followup study. Digestion 2007;75:113–21.
57. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997;9:353–59.
58. Masclee GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ. Is clostridium difficile associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis 2013;19: 2125–31.
59. Masclee GM, Penders J, Pierik M, Wolffs P, Jonkers D. Enteropathogenic viruses: triggers for exacerbation in IBD? A prospective cohort study using real-time quantitative polymerase chain reaction. Inflamm Bowel Dis 2013;19:124–31.
60. Munkholm P. Pregnancy, fertility, and disease course in patients with Crohn’s disease and ulcerative colitis. Eur J Intern Med 2000;11:215–21.
61. Reinders CA, Jonkers D, Janson EA et al. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease. Scand J Gastroenterol 2007;42:1151–57.
62. Salvarani C, Vlachonikolis IG, van der Heijde DM et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001;36:1307–13.
63. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119:1203–08.
64. Schoon EJ, Bollani S, Mills PR et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005;3:113–21.
65. Schoon EJ, Geerling BG, Van Dooren IM et al. Abnormal bone turnover in long-standing Crohn’s disease in remission. Aliment Pharmacol Ther 2001;15:783–92.
66. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: another pathogen-etic factor of osteoporosis in Crohn’s disease? Gut 2001;48: 473–77.
67. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000;232:43–47.
68. Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39: 690–97.
69. Witte J, Shivananda S, Lennard-Jones JE et al. Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol 2000;35:1272–77.
70. Wills ES, Jonkers DM, Savelkoul PH, Masclee AA, Pierik MJ, Penders J. Fecal microbial composition of ulcerative colitis and Crohn’s disease patients in remission and subsequent exacerbation. PLoS One 2014;9:e90981.
71. Zankel E, Rogler G, Andus T, Reng CM, Scholmerich J, Timmer A. Crohn’s disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol 2005;17:395–401.
72. Jeuring S, Bours P, Ambergen T et al. Effect of introduction of anti-tumour necrosis factor agents on the natural disease course of ulcerative colitis – a population-based IBD-SL study. Gastroenterology 144:S633.
73. Bodelier A, Pierik M, Dallinga J et al. Analysis of volatile organic compounds in exhaled air as a non invasive biomarker for inflammatory bowel disease (IBD). Gastroenterology 2009;136:A35.
74. Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol 2012;47:528–37.
75. Cellier C, Sahmoud T, Froguel E et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231–35.
76. Bodelier A, Jonkers D, van den Heuvel T et al. Diagnostic value of a novel combination score of disease activity in a real-life IBD cohort. Ecco congress. 2015;